Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Financial Officer | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 164,096 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 3,000 · Balance 164,096 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 157,030 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 9 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,030 Underlying: Common Stock · 157,030 shares Expires 2032-03-10 F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 25,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 8 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,124 Underlying: Common Stock · 25,465 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 4,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,659 Underlying: Common Stock · 4,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,767 Underlying: Common Stock · 3,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,792 Underlying: Common Stock · 768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,602 | $57.92 | $208,627.84 |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,005 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2022 Filed Apr 14, 2022 00:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 348 | $52.13 | $18,141.41 |
DisclosureSEC source: 0001127602-22-011957 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,353 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,817 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003847 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,560 Underlying: Common Stock · 1,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 767 | $63.90 | $49,011.30 |
DisclosureSEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,706 Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,616 | $67.34 | $243,501.44 |
DisclosureSEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,656 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 13,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,272 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,116 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029039 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,377 Underlying: Common Stock · 1,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 870 | $67.32 | $58,568.40 |
DisclosureSEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,015 Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 15, 2021 Filed Aug 24, 2021 22:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1 | $55.08 | $55.08 |
DisclosureSEC source: 0001127602-21-024261 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,972 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,290 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,605 | $69.29 | $111,210.45 |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,971 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,936 Underlying: Common Stock · 3,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F6 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 16,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,730 Underlying: Common Stock · 16,430 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 95,620 | $63.91 Strike: $63.91 | $6,111,074.20 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,620 Underlying: Common Stock · 95,620 shares Expires 2031-03-10 F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,771 | $63.91 | $113,184.61 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,930 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 15, 2021 Filed Mar 13, 2021 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 364 | $56.86 | $20,695.77 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,907 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's stock on February 15, 2021. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,300 Underlying: Common Stock · 1,818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 538 | $68.46 | $36,831.48 |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,543 Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 878 | $66.70 | $58,562.60 |
DisclosureSEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,263 Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,141 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2018. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 12,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,200 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 6, 2019, and March 10, 2020. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028870 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,118 Underlying: Common Stock · 1,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028870 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,031 Underlying: Common Stock · 1,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,399 | $60.62 | $84,807.38 |
DisclosureSEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,286 Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-023463 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,164 Underlying: Common Stock · 2,306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,022 | $68.51 | $70,017.22 |
DisclosureSEC source: 0001127602-20-023463 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,639 Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-023463 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,470 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,691 | $77.07 | $130,325.37 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,355 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 12,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,116 Underlying: Common Stock · 12,100 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Common Stock · 71,850 shares Expires 2030-03-10 F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,016 Underlying: Common Stock · 769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.